AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
Data-driven AI is improving the development of drugs. Expanding data access, coupled with advanced models and technologies like multimodality and clinical genomics, enables more precise target selection, patient stratification, and personalised treatments, promising higher success rates and greater returns on investment. This is an AI generated image.
About the authors
Remco Jan Geukes Foppen, PhD, is an AI and life sciences expert specialising in the pharmaceutical sector. With a global perspective, he integrates and implements AI-driven strategies that impact business decisions, always considering the human element. His leadership has driven international commercial success in areas including image analysis, data management, bioinformatics, advanced clinical trial data analysis leveraging machine learning and federated learning. Remco Jan Geukes Foppen’s academic background includes a PhD in biology and a master’s degree in chemistry, both from the University of Amsterdam.
Connect on LinkedIn >>
Vincenzo Gioia is an AI innovation strategist and a business and technology executive, with a 20-year focus on quality and precision for the commercialisation of innovative tools. Vincenzo specialises in artificial intelligence applied to image analysis, business intelligence and excellence. His focus on the human element of technology applications has led to high rates of solution implementation. He holds a master’s degree from University of Salerno in political sciences and marketing.
Connect on LinkedIn >>
Alessio Zoccoli applies AI for a sustainable future. His deep understanding of industry applications and technical expertise drives innovation in AI-powered solutions for complex business challenges. He specialises in cutting-edge advancements in natural language processing, computer vision, and generative AI. He is a senior data scientist and holds a master’s degree from Roma Tre University in computer engineering, where he also held the role of research fellow.
Connect on LinkedIn >>
Carlos N Velez, PhD, MBA, is a pharmaceutical and biotechnology strategic advisor, with 25 years’ experience in consulting, venture capital, corporate strategy and entrepreneurship. Carlos specialises in helping pharmaceutical and biotechnology companies develop their in- and out-licensing strategies, with additional expertise and experience in portfolio assessment and prioritisation, drug candidate valuation, valuation and related services. He also develops and presents customised training programmes (both live and virtual) for companies seeking to improve their in- and out-licensing processes. He holds a PhD in pharmacy from the University of North Carolina at Chapel Hill, and an MBA from the Rochester Institute of Technology.
Connect on LinkedIn >>